Healthcare

Japan issues draft review criteria for generative-AI medical devices

Japan’s medical-device regulator published draft review points specifically addressing generative AI, creating a clearer framework for healthcare developers.

Japan’s Pharmaceuticals and Medical Devices Agency published an English translation of draft review points for medical devices using generative AI. The material is described as Japan’s first explicit generative-AI review criteria for medical devices. The development provides manufacturers with a clearer regulatory framework for products that incorporate generative models. For healthcare technology companies, such guidance can affect product design, evidence generation, risk management and market-access planning. The source characterizes the criteria as an immediate compliance consideration for global manufacturers seeking access to Japan, although it identifies the document as a draft. The move reflects a broader shift from general AI principles toward device-specific oversight. Generative AI medical devices can behave differently from conventional fixed-function software, creating questions about performance variation, validation, updates and clinical risk. By issuing dedicated review points, Japan is signaling that these issues require explicit assessment within the medical-device pathway. The article does not report approval of a particular product or a completed regulatory decision. Its significance is instead institutional: manufacturers now have a more specific reference point for preparing generative-AI medical devices for Japanese review.

Original source: OriginBrief

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI